help button home button Am J Pathol ASIP 2008 Summer Academy, Molecular Methcanisms of Human Disease: Injury, Inflammation, and Tissue Repair
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heemann, U.
Right arrow Articles by Philipp, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heemann, U.
Right arrow Articles by Philipp, T.
(American Journal of Pathology. 2000;156:287-293.)
© 2000 American Society for Investigative Pathology

Regular Articles

Lipopolysaccharide Pretreatment Protects from Renal Ischemia/Reperfusion Injury

Possible Connection to an Interleukin-6-Dependent Pathway

Uwe Heemann*, Attila Szabo*{dagger}, Peter Hamar*{dagger}, Veronika Müller*{dagger}, Oliver Witzke*, Jens Lutz* and Thomas Philipp*

From the Department of Nephrology,*
University of Essen, Essen, Germany; and the Semmelweis Medical University,{dagger}
Budapest, Hungary

In vivo administration of low doses of lipopolysaccharide (LPS) to rodents can protect these animals from subsequently administrated, usually lethal doses of endotoxin or LPS. In this study we tested the effects of LPS pretreatment on ischemia/reperfusion injury in the kidney. Male C57/B1 mice were pretreated with different doses of LPS or phosphate-buffered saline on days -4 and -3. The right kidney was removed, and the vessels of the left kidney were clamped for 30 or 45 minutes on day 0. Creatinine levels and survival of animals were monitored. To test the involvement of cytokines, additional animals were harvested before ("time 0") and 15 minutes, 1, 2, 8, and 16 hours after reperfusion for histology, immunohistochemistry, terminal deoxynucleotidyltransferase-mediated UTP end-labeling assay, and reverse transcriptase-polymerase chain reaction analysis (including tumor necrosis factor (TNF)-{alpha}, interleukin (IL)-1, IL-6, inducible nitric oxide synthase (iNOS), and interferon (IFN)-{gamma} messenger RNA (mRNA)). In controls, renal ischemia of 30 minutes was nonlethal, whereas 73% of the animals died within 48 ± 18 hours, after 45 minutes of ischemia. All different doses of LPS protected the animals from lethal renal ischemia/reperfusion injury. Starting at similar levels, serum creatinine increased significantly in controls but not in LPS-pretreated animals over time. As early as 2 hours after reperfusion, tubular cell damage was significantly more pronounced in controls than in LPS-treated mice. In controls, tubules deteriorated progressively until 8 hours of reperfusion. At this time, more than 50% of tubular cells were destroyed. This destruction was accompanied by a pronounced leukocytic infiltration, predominantly by macrophages. In contrast, LPS pretreatment prevented the destruction of kidney tissue and infiltration by leukocytes. The terminal deoxynucleotidyltransferase-mediated UTP end-labeling assay revealed significantly more apoptotic cells in controls compared with LPS-pretreated animals. IL-1, IFN-{gamma}, and iNOS mRNA expression did not differ between the groups throughout the time points examined. However, the expression of TNF-{alpha} mRNA was significantly increased at 2 hours and IL-6 mRNA was significantly down-regulated before ischemia and shortly after reperfusion in the LPS-pretreated kidneys. Therefore, we found that sublethal doses of LPS induced cross-tolerance to renal ischemia/reperfusion injury. Our data suggest that increased TNF-{alpha} and reduced IL-6 mRNA expression might be responsible. However, more studies are needed to decipher the exact mechanism.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
Y.-J. Day, L. Huang, H. Ye, J. Linden, and M. D. Okusa
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F722 - F731.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. S. A. Patel, P. K. Chatterjee, R. Di Paola, E. Mazzon, D. Britti, A. De Sarro, S. Cuzzocrea, and C. Thiemermann
Endogenous Interleukin-6 Enhances the Renal Injury, Dysfunction, and Inflammation Caused by Ischemia/Reperfusion
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1170 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
A. Fekete, A. Vannay, A. Ver, B. Vasarhelyi, V. Muller, N. Ouyang, G. Reusz, T. Tulassay, and A. J. Szabo
Sex differences in the alterations of Na+,K+-ATPase following ischaemia-reperfusion injury in the rat kidney
J. Physiol., March 1, 2004; 555(2): 471 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
V. S. Vaidya, K. Shankar, E. A. Lock, D. Dixon, and H. M. Mehendale
Molecular Mechanisms of Renal Tissue Repair in Survival from Acute Renal Tubule Necrosis: Role of ERK1/2 Pathway
Toxicol Pathol, October 1, 2003; 31(6): 604 - 618.
[Abstract] [PDF]

Home page
 Innate ImmunityHome page
J.-M. Cavaillon, C. Adrie, C. Fitting, and M. Adib-Conquy
Endotoxin tolerance: is there a clinical relevance?
Innate Immunity, April 1, 2003; 9(2): 101 - 107.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
I. Friedrich, J. Spillner, E.-X. Lu, M. Barnscheidt, O. Kuss, A. Sablotzki, F. U. Schade, and J. Borgermann
Induction of endotoxin tolerance improves lung function after warm ischemia in dogs
Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L224 - L231.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. OKADA, S. F. YAN, and D. J. PINSKY
Peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets
FASEB J, December 1, 2002; 16(14): 1861 - 1868.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Shimizu, M. Tamamori-Adachi, H. Arai, N. Tabuchi, H. Tanaka, and M. Sunamori
Lipopolysaccharide pretreatment attenuates myocardial infarct size: A possible mechanism involving heat shock protein 70-inhibitory {kappa}B{alpha} complex and attenuation of nuclear factor {kappa}B
J. Thorac. Cardiovasc. Surg., November 1, 2002; 124(5): 933 - 941.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
M. Ackermann, M. Reuter, S. Flohe, S. Bahrami, H. Redl, and F. U. Schade
Cytokine synthesis in the liver of endotoxin-tolerant and normal rats during hemorrhagic shock
Innate Immunity, April 1, 2001; 7(2): 105 - 112.
[Abstract] [PDF]

Home page
 CirculationHome page
M. A. R. C. Daemen, V. H. Heemskerk, C. van 't Veer, G. Denecker, T. G. A. M. Wolfs, P. Vandenabeele, and W. A. Buurman
Functional Protection by Acute Phase Proteins {alpha}1-Acid Glycoprotein and {alpha}1-Antitrypsin Against Ischemia/Reperfusion Injury by Preventing Apoptosis and Inflammation
Circulation, September 19, 2000; 102(12): 1420 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. Rayhane, C. Fitting, O. Lortholary, F. Dromer, and J.-M. Cavaillon
Administration of Endotoxin Associated with Lipopolysaccharide Tolerance Protects Mice against Fungal Infection
Infect. Immun., June 1, 2000; 68(6): 3748 - 3753.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.